Frank L Jr Jaksch
CIK 1437237 · EXECUTIVE CHAIRMAN OF BOARD · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
39
Lifetime Open-Market Net
-$1.08M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NAGE | Director | — | $3.08 | — | $0 | 2 | 2026-06-26 |
| Niagen Bioscience, Inc. (CDXC) Delisted | EXECUTIVE CHAIRMAN OF BOARD | 2,356,392 | $7.87 | $18.54M | -$1.08M | 21 | 2024-12-13 |
Recent Filings · Page 2 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-06 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-27 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-12 | Niagen Bioscience, Inc. (CDXC) Delisted | Mixed | +18,944 | -$364 | EDGAR |
| 2019-02-22 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-17 | Niagen Bioscience, Inc. (CDXC) Delisted | — | — | $0 | EDGAR |
| 2018-05-16 | Niagen Bioscience, Inc. (CDXC) Delisted | Buy (P) | +9,800 | $35.2K | EDGAR |
| 2018-04-02 | Niagen Bioscience, Inc. (CDXC) Delisted | Mixed | — | -$47 | EDGAR |
| 2018-03-29 | Niagen Bioscience, Inc. (CDXC) Delisted | Mixed | — | -$2.5K | EDGAR |
| 2018-01-23 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-12 | Niagen Bioscience, Inc. (CDXC) Delisted | Mixed | — | -$57.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.